Earnings Ahead

VALN - Instrument

Instrument

Instrument

About

Profile


Headquarters


Intraday

High
-
Low
-

52-week

High
-
Low
-

VALN



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Valneva reports 1H results
  • Pfizer, Valneva post Phase 2 booster data for Lyme disease vaccine
  • Valneva falls as FDA extends review of chikungunya vaccine
  • WHO meeting is set to decide whether to end COVID emergency
  • Valneva reports Q1 results
  • WHO chief expects COVID emergency to end this year
  • Valneva, Pfizer delay end date of Lyme disease vaccine phase 3 trial to 2025
  • Valneva GAAP EPS of €1.24, revenue of €361.3M; issues FY23 guidance
  • Valneva COVID shot shelf life extended; gets EMA nod for booster; shows efficacy in trials
  • Valneva's single-shot chikungunya vaccine VLA1553 gets FDA priority review
  • Pfizer, Valneva removes ~50% participants in Lyme disease vaccine trial on violation woes
  • Valneva reports FY results; issues FY23 guidance
  • Valneva finishes enrolling in phase 3 trial of single-shot chikungunya vaccine in adolescents
  • WHO maintains public health emergency on COVID but sees pandemic at 'transition point'
  • WHO sets Jan. 27 meeting to decide on COVID emergency
  • Valneva stock rises as it seeks FDA approval of single-shot chikungunya vaccine
  • WHO chief hopeful COVID emergency will end next year
  • Valneva dips as French health authority advises against COVID shot
  • Pfizer, Valneva Lyme disease vaccine shows antibodies 6-month after vaccination
  • Valneva reports Q3 results; reaffirms FY22 guidance